Table 2 GWAS results with q-value <0.5

From: Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D

Side effect

Locus

Test

 

Chr

Position

SNP ID

Gene

MAF

MA

N

P-value

q-value

Effect

Visionhearing

7

100 902 714

rs17135437

EMID2

0.019

A

1675

3.27E-08

0.026

+

Overall tolerability

18

6 931 108

rs4398173

LAMA1

0.460

G

1691

5.99E-07

0.315

+

Overall tolerability

18

6 931 662

rs3810046

LAMA1

0.456

T

1700

4.78E-07

0.281

+

Overall tolerability

16

13 564 386

rs2903308

 

0.461

T

1687

1.69E-06

0.496

+

GSE

5

38 488 651

rs7715172

EGFLAM

0.071

G

1706

2.91E-06

0.358

+

GSE

3

59 896 060

rs4502542

FHIT

0.017

T

1690

1.62E-06

0.262

+

GSE

13

83 028 233

rs6563353

 

0.177

A

1666

2.06E-06

0.299

+

GSE

13

104 605 024

rs16965962

 

0.030

T

1706

3.22E-07

0.096

+

GSE

X

116 106 291

rs6646773

 

0.076

C

1704

1.30E-06

0.231

+

GSE

4

187 575 329

rs11935103

 

0.262

T

1705

1.33E-06

0.234

+

GSE

3

188 896 685

rs6764050

RPT2

0.023

G

1706

8.73E-07

0.182

+

Dizziness

20

11 105 011

rs6040399

 

0.308

T

1684

6.89E-07

0.216

+

Dizziness

2

201 356 884

rs13430864

AOX2P

0.040

G

1671

5.12E-07

0.181

+

Dizziness

2

201 360 698

rs13423450

AOX2P

0.040

C

1689

7.57E-07

0.228

+

  1. Abbreviations: Chr, chromosome number; effect, direction of the effect of minor allele; GSE, general side effect burden; GWAS, genome-wide association study; LD, linkage disequilibrium; MA, minor allele; MAF, minor allele frequency; N, sample size; SNP, single-nucleotide polymorphism.
  2. Locus information includes Chr and location of SNP (bp, Genome Build 36.3). Direction of effect is properly interpreted as ‘+’, indicating that the MA is associated with increased side effect burden. Rows in bold indicate SNPs in high LD (r2>0.8) with each other.
Back to article page